Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Nov avax的 Nuvaxovid，是拿到美国FDA监管授权的第四款 COVID-19疫苗。由于获批时间（于2022年 7月获批）上 落后， Nuvaxovid的销售数据在2022年和2023年远远低于两款 COVID-19 mRNA疫苗。

Nuvaxovid 由诺瓦瓦克斯与 赛诺菲 （Sanofi）合作开发，后者将根据里程碑协议向诺瓦瓦克斯支付 1.75 亿美元，未来还可能从疫苗销售中支付更多特许权使用费。 该制药商表示，FDA 批准了其针对 Nuvaxovid ...

Novavax (NVAX.US) 获得美国食品药物管理局 (FDA)Covid-19疫苗的批准，将可与辉瑞 (PFE.US) 及莫德纳 (MRNA.US) 等对手竞争。该股周一早段抽升22%。

在经过为期六周的审评延迟后，美国FDA刚刚批准了诺瓦瓦克斯 (Novavax) 公司研制的新冠疫苗Nuvaxovid的上市许可，适用于65岁及以上人群以及12岁及以上伴有至少一种重症高风险基础疾病的人群。

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

近日，诺瓦瓦克斯（Novavax）因其新型蛋白基新冠疫苗Nuvaxovid获得美国食品药品监督管理局（FDA）批准，股价在开盘时暴涨25%。这一事件不仅引发了市场的强烈反应，也让公众对新冠疫苗的选择和未来的疫苗接种策略产生了更深层的思考。

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...

The U.S. Food and Drug Administration approved Novavax's Covid-19 vaccine with age restrictions after a six-week delay.